Abhenil Mittal
@abhenilmittal
Followers
1K
Following
2K
Media
38
Statuses
1K
MedOnc, Asst Prof at NOSMU,Breast, GU and Thoracic Cancers, Health service researcher, Coffee and sports lover, 🇮🇳 to 🇨🇦, Opinions my own
Greater Sudbury / Grand Sudbur
Joined June 2011
U of T fellowship graduation ceremony! Humbled at the opportunity to have trained at such a great institution! Excited for the road ahead!.@UofT_DoM @UofT @pmcancercentre
22
3
82
RT @oncology_bg: This is probably the most important publication we have published for trainees and senior oncologists alike. This provides….
0
89
0
RT @OncNewsCentral: Critics argue the #ARANOTE trial used an inferior control arm for #mHSPC, despite current standards favoring #Docetaxel….
oncologynewscentral.com
Critics allege that some pharmaceutical industry–run cancer trials stack the deck in their favor by using outmoded standards of care to compare with new drugs.
0
3
0
RT @DrMarkLythgoe: Very interesting letter from @oncology_bg (and co)about use of below sub-optimal control arms to adulate clinical outcom….
ascopubs.org
0
7
0
RT @dr_yakupergun: An excellent letter regarding the design of the ARANOTE trial. I sincerely congratulate the authors. I had also submitt….
0
9
0
RT @pash22: Putting up with Inferior Control Arms in Prostate Cancer Trials: The ARANOTE Trial.via @abhenilmittal &….
0
11
0
0
0
0
Thanks Bishal! It was sad to see a metastatic HSPC trial enrolling patients to a control arm of ADT when 4 different life prolonging therapies were already approved before it started enrolling! . WE MUST DO BETTER FOR OUR PATIENTS!. @JCO_ASCO.
Please do read our letter to editor to @JCO_ASCO with regards to the recent publication of the ARANOTE trial. Until when shall we put up with inferior control arms? .Congratulations @abhenilmittal for raising awareness re this important issue.
3
2
11
RT @ErikaHamilton9: It's a difficult topic to discuss- weight. Hugely personal, not easy to change, but impt. 4% ⬆️ recurrence in pts w/ n….
0
24
0
RT @gusviani: Do all early-stage breast cancer patients need axillary surgery? The INSEMA trial challenges this long-standing practice, sho….
0
70
0
Excellent summary by @oncology_bg on our recent paper on #SurrogateEndPoints in @eClinicalMed @TheLancet.
Surrogate endpoints in oncology trials remain controversial. Our latest article answers 15 common questions, addressing pitfalls and the way forward. Learn why OS and QoL should be the gold standards. #ClinicalTrials @oncology_bg @TheLancet.
1
2
5
RT @oncology_bg: What questions can you think of regarding surrogate endpoints in oncology?.We try to answer them all in this review. This….
0
30
0
Thank you @oncology_bg and @Claudia_Editor for the opportunity. Hopefully this paper would be a good resource for anyone interested in reading about surrogate end points in oncology! @drbrookewilson @csoncol @HSN_Sudbury @thenosm.
SIMULTANEOUS PUBLICATION ALERT!🚨 . As I mentioned in my talk, a comprehensive review answering most frequently asked questions on surrogate endpoints in oncology has been simultaneously published in @eClinicalMed today with our @myESMO MCBS session. OPEN ACCESS.
1
3
20
Immunotherapy toxicity week- rash, hepatitis, colitis, pneumonitis! 😳 .comes in waves!!.
1
0
5
RT @CDNCancerTrials: The biennial New Investigator Clinical Trials Course #NICTC2024 was kicked off this morning with an EDIIA session dis….
0
3
0
Thanks Maria. It was a pleasure working with you and the entire team. Lots of work to do to make clinical trial access equitable for patients and the process of running a trial easier and less cumbersome for investigators! @CDNCancerTrials @ASCO @navstruck @pwheatleyprice.
A pleasure working with this fantastic team to highlight barriers, challenges, and potential solutions for oncology trials. @abhenilmittal, Sara Moore, @navstruck, Dave Stewart, Geoff Liu, @pwheatleyprice .@pmcancercentre.
0
1
1
@navstruck @pwheatleyprice @FordePatrick @lungoncdoc @ADesaiMD @SauraVermaMD @Mig lG_pds ht @JackWestMD.
0
0
0
Similarly, for PDL1 high unresectable NSCLC, with plateau in PFS curves seen with IO, is PACIFIC approach the right way or treating with systemic therapy alone till progression? . We need ctDNA and other biomarkers to make these decisions .#ASCO24 #lungcancer.
1
0
0
Something we need to think about and acknowledge as we discuss with patients. Unresectable stage III NSCLC is likely incurable and needs ongoing systemic therapy. Question is- do they need the toxicity of chemoradiation when effective TKI’s are available?
1
0
4